Type of information: Private placement
Company: Aurinia Pharmaceuticals (Canada)
Amount: $173.1 million
Funding type: private placement
Planned used: Aurinia Pharmaceuticals intends to use the net proceeds of the Offering for research and development activities, including Phase 3 clinical trial activities for lupus nephritis, and working capital purposes. The company is currently developing voclosporin for the treatment of lupus nephritis.
Others: * On March 20, 2017, Aurinia Pharmaceuticals announced the closing of its previously announced underwritten public offering of 25,645,000 common shares, including 3,345,000 common shares pursuant to the full exercise of the underwriters’ option to purchase additional common shares. The shares were sold at a public offering price of US$6.75 per share. The gross offering proceeds to the Company from this Offering are approximately US$173.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
Therapeutic area: Autoimmune diseases - Immunological diseases